MeSH term
Frequency | Condition_Probility | Female | 131 | 0.0 |
Follow-Up Studies | 9 | 0.0 |
Humans | 250 | 0.0 |
Male | 146 | 0.0 |
Middle Aged | 86 | 0.0 |
Treatment Outcome | 6 | 0.0 |
Animals | 37 | 0.0 |
English Abstract | 97 | 0.0 |
Kidney/enzymology | 2 | 1.0 |
Liver/enzymology | 6 | 1.0 |
Rats | 16 | 0.0 |
Rats, Wistar | 4 | 0.0 |
Adult | 91 | 0.0 |
Aged | 44 | 0.0 |
Comparative Study | 35 | 0.0 |
Dose-Response Relationship, Drug | 5 | 0.0 |
Infusions, Intravenous | 2 | 0.0 |
Probability | 2 | 0.0 |
Prospective Studies | 8 | 0.0 |
Reference Values | 5 | 0.0 |
Survival Rate | 2 | 0.0 |
Anorexia/chemically induced | 2 | 28.0 |
*Anthracyclines | 2 | 66.0 |
Antibiotics, Antineoplastic/adverse effects/*therapeutic use | 2 | 25.0 |
Drug Administration Schedule | 4 | 0.0 |
Leukopenia/chemically induced | 3 | 16.0 |
Thrombocytopenia/chemically induced | 2 | 10.0 |
Base Sequence | 9 | 0.0 |
Research Support, Non-U.S. Gov't | 68 | 0.0 |
Cholesterol/blood | 5 | 0.0 |
*Polymorphism, Genetic | 16 | 0.0 |
Triglycerides/blood | 5 | 0.0 |
Aged, 80 and over | 7 | 0.0 |
Alanine Transaminase/blood | 42 | 21.0 |
Aspartate Aminotransferases/blood | 30 | 22.0 |
Blood Urea Nitrogen | 3 | 5.0 |
Retrospective Studies | 5 | 0.0 |
Aging/*metabolism | 2 | 0.0 |
Oxidation-Reduction | 2 | 0.0 |
Sex Factors | 5 | 0.0 |
Blood Cell Count | 5 | 2.0 |
Blood Chemical Analysis | 3 | 6.0 |
Adolescent | 30 | 0.0 |
Alkaline Phosphatase/blood | 10 | 6.0 |
Bilirubin/blood | 8 | 8.0 |
Liver/*physiopathology | 3 | 21.0 |
Administration, Oral | 2 | 0.0 |
Blood Glucose/analysis | 3 | 0.0 |
Double-Blind Method | 3 | 0.0 |
Liver Function Tests | 13 | 7.0 |
Enzymes/blood | 3 | 23.0 |
Platelet Count | 2 | 0.0 |
Prothrombin Time | 2 | 1.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Mice | 9 | 0.0 |
Analysis of Variance | 3 | 0.0 |
L-Lactate Dehydrogenase/metabolism | 5 | 3.0 |
Tumor Cells, Cultured | 4 | 0.0 |
Acute Disease | 6 | 0.0 |
Alanine Transaminase/*blood | 15 | 60.0 |
Aspartate Aminotransferases/*blood | 7 | 63.0 |
Biological Markers/blood | 6 | 0.0 |
Creatine Kinase/*blood | 2 | 5.0 |
Myoglobin/*blood | 2 | 25.0 |
Predictive Value of Tests | 2 | 0.0 |
Time Factors | 15 | 0.0 |
Germany | 2 | 0.0 |
Infant, Newborn | 4 | 0.0 |
Pregnancy | 3 | 0.0 |
Biopsy | 3 | 0.0 |
Tumor Markers, Biological/analysis | 2 | 0.0 |
*Liver Function Tests | 5 | 50.0 |
Polymerase Chain Reaction | 7 | 0.0 |
RNA, Viral/blood | 3 | 0.0 |
Diagnosis, Differential | 4 | 0.0 |
Lipids/*blood | 2 | 0.0 |
Liver/*drug effects/enzymology | 2 | 4.0 |
Africa, Central | 2 | 33.0 |
Creatine Kinase/blood | 6 | 5.0 |
Liver/pathology | 6 | 3.0 |
gamma-Glutamyltransferase/blood | 9 | 18.0 |
Alanine Transaminase/*metabolism | 2 | 25.0 |
Alanine Transaminase/metabolism | 6 | 30.0 |
Aspartate Aminotransferases/metabolism | 5 | 27.0 |
Child | 24 | 0.0 |
Child, Preschool | 15 | 0.0 |
Drug Therapy, Combination | 6 | 0.0 |
Infant | 16 | 0.0 |
*Apoptosis | 2 | 0.0 |
Liver/*pathology | 3 | 5.0 |
Necrosis | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 18 | 0.0 |
Lipids/blood | 2 | 0.0 |
Area Under Curve | 2 | 0.0 |
Hematocrit | 2 | 0.0 |
Kidney Transplantation/*physiology | 2 | 4.0 |
Regression Analysis | 4 | 0.0 |
Tissue Donors | 2 | 0.0 |
Prognosis | 8 | 0.0 |
*Postoperative Complications | 2 | 3.0 |
Multivariate Analysis | 2 | 0.0 |
Alanine Transaminase/*genetics | 9 | 47.0 |
Amino Acid Sequence | 4 | 0.0 |
Isoenzymes/genetics | 2 | 0.0 |
Molecular Sequence Data | 9 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Hepacivirus/*genetics | 3 | 12.0 |
Alanine Transaminase/blood/metabolism | 2 | 100.0 |
Aspartate Aminotransferases/blood/metabolism | 2 | 100.0 |
Chronic Disease | 16 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Rabbits | 2 | 0.0 |
Cells, Cultured | 6 | 0.0 |
L-Lactate Dehydrogenase/blood | 8 | 7.0 |
Liver/metabolism | 2 | 0.0 |
Prevalence | 3 | 0.0 |
Risk Factors | 3 | 0.0 |
Recurrence | 2 | 0.0 |
Remission Induction | 2 | 0.0 |
*DNA Damage | 2 | 0.0 |
DNA Primers/genetics | 2 | 0.0 |
DNA Transposable Elements | 2 | 1.0 |
Genes, Bacterial | 2 | 1.0 |
Genetic Markers | 9 | 0.0 |
Genetic Vectors | 2 | 0.0 |
Genotype | 7 | 0.0 |
Hybrid Cells | 2 | 0.0 |
Hypoxanthine Phosphoribosyltransferase/*genetics | 2 | 4.0 |
Phenotype | 26 | 0.0 |
Recombination, Genetic | 5 | 0.0 |
Hepatitis B Antibodies/analysis | 2 | 11.0 |
Hepatitis B virus/immunology | 2 | 11.0 |
Family | 2 | 0.0 |
Pedigree | 10 | 0.0 |
Japan | 8 | 0.0 |
Alanine Transaminase/genetics | 3 | 33.0 |
*Chromosome Mapping | 4 | 0.0 |
Hamsters | 4 | 0.0 |
Hepatic Artery | 2 | 3.0 |
*Mutation | 2 | 0.0 |
Plasmids | 3 | 0.0 |
Mass Screening | 3 | 1.0 |
Azacitidine/pharmacology | 2 | 4.0 |
Cell Line | 8 | 0.0 |
Cricetulus | 2 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
Ursodeoxycholic Acid/therapeutic use | 2 | 33.0 |
Respiratory Tract Infections/drug therapy | 2 | 66.0 |
Urinary Tract Infections/drug therapy | 3 | 75.0 |
Muscles/enzymology | 2 | 3.0 |
Blood Transfusion/adverse effects | 2 | 5.0 |
Fructose-Bisphosphate Aldolase/*analysis | 2 | 100.0 |
Isoenzymes/*analysis | 2 | 4.0 |
Radioimmunoassay | 2 | 0.0 |
Enzymes/*blood | 3 | 25.0 |
Escherichia coli/genetics | 2 | 0.0 |
Solubility | 2 | 0.0 |
Liver/*metabolism | 2 | 0.0 |
Postoperative Period | 2 | 0.0 |
Transaminases/*blood | 3 | 42.0 |
Blood Group Antigens/*genetics | 4 | 3.0 |
Blood Proteins/*genetics | 7 | 4.0 |
Polymorphism, Genetic | 7 | 0.0 |
*Linkage (Genetics) | 8 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Hepatitis B Antibodies/*analysis | 5 | 38.0 |
Mutation | 2 | 0.0 |
Alanine Transaminase/analysis | 2 | 25.0 |
Injections, Intramuscular | 2 | 1.0 |
Urinary Tract Infections/*drug therapy | 2 | 50.0 |
Lactates/blood | 2 | 2.0 |
Cytosol/enzymology | 2 | 1.0 |
Liver/*enzymology | 3 | 0.0 |
Drug Evaluation | 8 | 3.0 |
Erythrocytes/*enzymology | 11 | 2.0 |
Gene Frequency | 20 | 0.0 |
Heterozygote | 4 | 0.0 |
USSR | 4 | 22.0 |
Pseudocholinesterase/blood | 2 | 40.0 |
Antibodies, Viral/analysis | 3 | 2.0 |
*Blood Donors | 2 | 1.0 |
*Enzyme Tests | 2 | 3.0 |
Isoenzymes | 2 | 1.0 |
Alkaline Phosphatase/*blood | 4 | 11.0 |
Deoxycholic Acid/*analogs & derivatives | 2 | 66.0 |
Ursodeoxycholic Acid/*therapeutic use | 2 | 40.0 |
gamma-Glutamyltransferase/*blood | 2 | 18.0 |
Hepatitis B e Antigens/analysis | 2 | 13.0 |
Cholinesterases/*blood | 2 | 11.0 |
In Vitro | 4 | 0.0 |
Leucyl Aminopeptidase/blood | 3 | 60.0 |
*Genes, Structural | 2 | 0.0 |
Age Factors | 5 | 0.0 |
Body Weight | 2 | 0.0 |
Italy | 5 | 0.0 |
Alleles | 10 | 0.0 |
Demography | 2 | 1.0 |
Heterozygote Detection | 3 | 0.0 |
Isoenzymes/blood/*genetics | 3 | 13.0 |
Hepatitis B/*immunology | 3 | 9.0 |
Protein Precursors/*analysis/immunology | 2 | 100.0 |
Clinical Trials | 3 | 0.0 |
Parenteral Nutrition, Total/*adverse effects | 2 | 40.0 |
Carrier State/immunology | 2 | 13.0 |
Hepatitis B Antigens/*immunology | 2 | 40.0 |
Enzymes/*genetics | 4 | 9.0 |
*Genetics, Population | 7 | 1.0 |
Phosphoglucomutase/genetics | 2 | 4.0 |
*Variation (Genetics) | 2 | 0.0 |
Selection (Genetics) | 2 | 1.0 |
Half-Life | 3 | 0.0 |
*Gene Frequency | 6 | 1.0 |
Isoelectric Focusing | 5 | 0.0 |
Bulgaria | 2 | 13.0 |
Species Specificity | 3 | 0.0 |
Chromosome Banding | 3 | 0.0 |
Erythrocytes/enzymology | 4 | 1.0 |
*Gene Expression Regulation | 2 | 0.0 |
Karyotyping | 3 | 0.0 |
*Chromosomes, Human, Pair 16 | 2 | 0.0 |
Kinetics | 2 | 0.0 |
Liver/drug effects/*enzymology/pathology | 2 | 50.0 |
Rats, Inbred Strains | 3 | 0.0 |
Drug Combinations | 3 | 0.0 |
Tablets | 2 | 5.0 |
Immunoglobulin M/*analysis | 2 | 4.0 |
Linkage (Genetics) | 4 | 0.0 |
Alanine Transaminase/blood/*genetics | 5 | 83.0 |
Blood Group Antigens/genetics | 3 | 5.0 |
*Paternity | 3 | 4.0 |
Enzymes/blood/*genetics | 4 | 66.0 |
Escherichia coli/enzymology/*genetics | 2 | 11.0 |
Pentosyltransferases/*genetics | 2 | 13.0 |
*Genetic Markers | 3 | 0.0 |
Genes, Dominant | 2 | 0.0 |
*Chromosome Deletion | 2 | 0.0 |
European Continental Ancestry Group | 2 | 0.0 |
Hepatitis B Surface Antigens/*analysis | 2 | 6.0 |
Acclimatization | 2 | 20.0 |
Creatinine/blood | 2 | 0.0 |
Blood Proteins/analysis | 2 | 1.0 |
Injections, Intravenous | 2 | 0.0 |
Liver Diseases, Alcoholic/*enzymology | 2 | 25.0 |
Bacterial Infections/*drug therapy | 3 | 50.0 |
Respiratory Tract Infections/*drug therapy | 3 | 60.0 |
ABO Blood-Group System/genetics | 3 | 7.0 |
Rh-Hr Blood-Group System/genetics | 3 | 10.0 |
*Ethnic Groups | 3 | 2.0 |
Bilirubin/*blood | 2 | 9.0 |
L-Lactate Dehydrogenase/*blood | 3 | 10.0 |
Chromosome Aberrations | 2 | 0.0 |
Hepatitis, Toxic/*etiology | 2 | 40.0 |
Genes, Structural | 2 | 0.0 |
Blood Proteins/genetics | 3 | 5.0 |
Antibodies, Viral/*analysis | 2 | 3.0 |
Neoplasm Metastasis | 2 | 0.0 |
Antibody Formation | 2 | 0.0 |
Herpesvirus 4, Human/immunology | 2 | 2.0 |
Immunoglobulins/analysis | 2 | 0.0 |
Alcohol Dehydrogenase | 2 | 40.0 |
Alcoholism/*enzymology | 2 | 14.0 |
Blood Donors | 3 | 1.0 |
Creatine Kinase/metabolism | 2 | 5.0 |
Leukocyte Count | 2 | 0.0 |
Infusions, Parenteral | 2 | 1.0 |
*African Continental Ancestry Group | 2 | 1.0 |
South Africa | 2 | 1.0 |
Liver Diseases/*immunology | 2 | 10.0 |
*Alleles | 4 | 0.0 |
Electrophoresis | 2 | 0.0 |
*Lod Score | 2 | 5.0 |
Lipoproteins, HDL/blood | 2 | 0.0 |
Lipoproteins, HDL Cholesterol | 2 | 4.0 |
African Continental Ancestry Group | 2 | 0.0 |
Chromosome Mapping | 2 | 0.0 |
Contraceptives, Oral/*pharmacology | 2 | 9.0 |
Aminohydrolases/*blood | 2 | 100.0 |
Dogs | 2 | 0.0 |
Guanine Deaminase/*blood | 2 | 100.0 |
Transaminases/blood | 2 | 11.0 |
Asian Continental Ancestry Group | 2 | 0.0 |
Liver Diseases/*enzymology | 2 | 15.0 |
Homozygote | 2 | 0.0 |
Evaluation Studies | 3 | 0.0 |
Glutamate Dehydrogenase/blood | 2 | 50.0 |
Liver/*drug effects | 2 | 13.0 |
Acid Phosphatase/blood | 3 | 4.0 |
Adenylate Kinase/blood | 3 | 30.0 |
Esterases/blood | 3 | 25.0 |
Phosphoglucomutase/blood | 3 | 18.0 |
Hydroxybutyrate Dehydrogenase/blood | 2 | 15.0 |
*Infant, Newborn | 2 | 4.0 |
*Alanine Transaminase | 3 | 100.0 |
*Phenotype | 2 | 0.0 |
Staining and Labeling | 2 | 0.0 |
